ClinicalTrials.gov
ClinicalTrials.gov Menu

Increased Activity of ENaC in Proteinuric Kidney Transplant Recipients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03036748
Recruitment Status : Not yet recruiting
First Posted : January 30, 2017
Last Update Posted : January 30, 2017
Sponsor:
Collaborators:
Odense University Hospital
Region of Southern Denmark
Information provided by (Responsible Party):
Gitte Rye Hinrichs, University of Southern Denmark

Brief Summary:
The aim of this study is to determine if amiloride, a diuretic drug, is capable of increasing renal salt excretion, lowering blood pressure and inhibiting uPA in kidney transplant recipients with proteinuria compared to normoalbuminuric transplant patients.

Condition or disease Intervention/treatment Phase
Kidney Transplant; Complications Dietary Supplement: Standardized sodium diet Drug: Tbl amiloride Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Experimental: Kidney transplant recipients with ACR > 300mg/g receiving first a standardized salt diet (150 mmol NaCl/day) for 4 days and then amiloride tablet 20 mg two times daily (morning and afternoon) for one day.

Interventions:◦Dietary Supplement: Standardized salt diet

◦Drug: Amiloride

•Experimental: Kidney transplant recipient with ACR< 30mg/g (Control) receiving a standardized salt diet (150 mmol NaCl/day) for 4 days, then amiloride tablet 20 mg two times daily (morning and afternoon) for 1 day.

Interventions:◦Dietary Supplement: Standardized salt diet

◦Drug: Amiloride

Masking: None (Open Label)
Masking Description: open label
Primary Purpose: Basic Science
Official Title: Increased Activity of ENaC in Proteinuric Kidney Transplant Recipients
Estimated Study Start Date : February 1, 2017
Estimated Primary Completion Date : February 1, 2018
Estimated Study Completion Date : February 1, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Kidney transplant recipients with ACR <30mg/g Dietary Supplement: Standardized sodium diet
Dietary Supplement: Standardized salt diet 150 mmol NaCl per day given as three meals daily for 6 consecutive days.

Drug: Tbl amiloride
Drug: Amiloride Amiloride tablet 10-20 mg two times daily (morning and afternoon) for one day

Experimental: Kidney transplant recipients with ACR> 300mg/g Dietary Supplement: Standardized sodium diet
Dietary Supplement: Standardized salt diet 150 mmol NaCl per day given as three meals daily for 6 consecutive days.

Drug: Tbl amiloride
Drug: Amiloride Amiloride tablet 10-20 mg two times daily (morning and afternoon) for one day




Primary Outcome Measures :
  1. 24-hour urinary sodium excretion induced by amiloride [ Time Frame: Change from baseline urinary sodium excretion at 24 hours after amiloride administration ]

Secondary Outcome Measures :
  1. Office or 24h blood pressure measurements [ Time Frame: Change from baseline office blood pressure at day 4 of salt diet and at 24 hours after amiloride administration ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • One Group of kidney transplant recipients with ACR< 30mg/g
  • One Group of kidney transplant recipients with ACR >300mg/g
  • Negative pregnancy test at inclusion and taking contraceptive medication

Exclusion Criteria:

  • Receiving amiloride, glucocorticoids, aldosterone or spironolactone
  • Clinically relevant organic or systemic disease including malignancy
  • eGFR or creatinin-clearance < 30ml/min
  • hyperkalemia (s-potassium > 5,0mmol/l)

Responsible Party: Gitte Rye Hinrichs, MD, University of Southern Denmark
ClinicalTrials.gov Identifier: NCT03036748     History of Changes
Other Study ID Numbers: ENaC activation
First Posted: January 30, 2017    Key Record Dates
Last Update Posted: January 30, 2017
Last Verified: January 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Amiloride
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Acid Sensing Ion Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Epithelial Sodium Channel Blockers
Diuretics, Potassium Sparing